At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4556 Gene Editing
Not Yet Opened 04-28 16:00:00 EDT
466.94
+12.93
+2.85%
High473.99Low449.14Vol23.89M
Open453.52D1 Closing454.02Amplitude5.47%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O364.01MT/O Rate--Tradable Shares0.00
P/B2.534455ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-Sangamo Therapeutics To Transition Common Stock To Otcqb Venture Market On May 5, 2026
Reuters  ·  20:09
BRIEF-Sangamo Therapeutics To Transition Common Stock To Otcqb Venture Market On May 5, 2026
Sangamo shares set to move to OTCQB as Nasdaq delists stock May 5
Reuters  ·  20:09
Sangamo shares set to move to OTCQB as Nasdaq delists stock May 5
Sangamo Therapeutics Inc - to Transition Common Stock to Otcqb Venture Market on May 5, 2026
THOMSON REUTERS  ·  20:05
Sangamo Therapeutics Inc - to Transition Common Stock to Otcqb Venture Market on May 5, 2026
Press Release: Morningstar Reaches New Milestone in the CRSP Acquisition, Rebranding CRSP Market Indexes to Morningstar Indexes
Dow Jones  ·  20:00
Press Release: Morningstar Reaches New Milestone in the CRSP Acquisition, Rebranding CRSP Market Indexes to Morningstar Indexes
BUZZ-Gene-editing firm Intellia falls on $180 mln stock sale
Reuters  ·  19:51
BUZZ-Gene-editing firm Intellia falls on $180 mln stock sale
Intellia Therapeutics Inc - Public Offering Price Set at $10.75 per Share
THOMSON REUTERS  ·  19:00
Intellia Therapeutics Inc - Public Offering Price Set at $10.75 per Share
Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing
Simply Wall St.  ·  09:18
Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing
Editas Medicine announces annual shareholder meeting via virtual webcast
Reuters  ·  04:54
Editas Medicine announces annual shareholder meeting via virtual webcast
Intellia Therapeutics Inc : Canaccord Genuity Raises Target Price to $58 From $48
THOMSON REUTERS  ·  04-28 12:58
Intellia Therapeutics Inc : Canaccord Genuity Raises Target Price to $58 From $48
Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)
TIPRANKS  ·  04-28 12:40
Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)
Intellia Therapeutics Inc : Leerink Partners Raises Target Price to $35 From $29
THOMSON REUTERS  ·  04-28 11:41
Intellia Therapeutics Inc : Leerink Partners Raises Target Price to $35 From $29
Intellia Therapeutics Launches $150 Million Stock Offering
MT Newswires Live  ·  04-28 05:36
Intellia Therapeutics Launches $150 Million Stock Offering
Editas Medicine to present preclinical data for EDIT-401 hyperlipidemia therapy at conferences
Reuters  ·  04-28 04:33
Editas Medicine to present preclinical data for EDIT-401 hyperlipidemia therapy at conferences
Intellia Therapeutics Inc - Commences $150 Mln Underwritten Public Offering of Common Stock
THOMSON REUTERS  ·  04-28 04:01
Intellia Therapeutics Inc - Commences $150 Mln Underwritten Public Offering of Common Stock
Press Release: Intellia Announces Proposed Public Offering of Common Stock
Dow Jones  ·  04-28 04:01
Press Release: Intellia Announces Proposed Public Offering of Common Stock
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Biogen (BIIB)
TIPRANKS  ·  04-27 20:30
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Biogen (BIIB)
Intellia Therapeutics Reports Positive Phase 3 Trial Results for CRISPR-Based Gene Therapy
Deep News  ·  04-27 20:11
Intellia Therapeutics Reports Positive Phase 3 Trial Results for CRISPR-Based Gene Therapy
Intellia Therapeutics Shares Jump 8% Premarket After Rare Genetic Disorder Therapy Meets Main Goal in Trial
THOMSON REUTERS  ·  04-27 19:35
Intellia Therapeutics Shares Jump 8% Premarket After Rare Genetic Disorder Therapy Meets Main Goal in Trial
Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial
Reuters  ·  04-27 19:05
Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial
Intellia starts rolling FDA BLA submission for lonvo-z in hereditary angioedema
Reuters  ·  04-27 19:02
Intellia starts rolling FDA BLA submission for lonvo-z in hereditary angioedema

Introduction

Company Name.
BK4556
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--